Important Update for Investors in Caribou Biosciences, Inc. Regarding Class Action Lawsuit

Call to Action for Caribou Biosciences Investors

In light of recent developments, investors in Caribou Biosciences, Inc. are urged to reach out to Levi & Korsinsky, LLP as soon as possible. The legal firm is actively representing shareholders in a significant class action lawsuit against Caribou Biosciences, which is notably traded on NASDAQ under the symbol CRBU. This communication serves as a vital notice for those who may have been affected by alleged securities fraud during a specific timeframe.

Background on the Lawsuit

The class action lawsuit seeks to recover losses incurred by investors between July 14, 2023, and July 16, 2024. It alleges that the company's representatives made misleading and erroneous statements regarding the safety, efficacy, and overall performance of their product, CB-010. Specifically, the lawsuit claims that Caribou overstated the capabilities of CB-010 in comparison to approved CAR-T cell therapies utilized for treating various cancers, such as relapsed or refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and large B-cell lymphoma (LBCL).

Moreover, it alleges that Caribou was at substantial risk of not having enough capital to sustain its operations, particularly regarding the funding of necessary preclinical research associated with its allogeneic CAR-NK platform. This situation, the lawsuit claims, has had a profoundly negative impact on the company's operational stability, thereby misleading investors about the company's health and future prospects.

What Should Investors Do?

Investors who believe they were adversely impacted by these alleged fraudulent statements have until February 24, 2025, to appear as lead plaintiffs in court. It’s crucial to understand that participating in this lawsuit comes at no cost to you as a class member; there is no requirement for out-of-pocket expenses or fees.

If you suffered losses during the class period, reach out to Levi & Korsinsky promptly. Those looking for further details can contact Joseph E. Levi, Esq., either via email or phone at (212) 363-7500. More proactive investors may fill out an online submission form available through Levi & Korsinsky's website to facilitate the discussion regarding their individual rights.

Why Choose Levi & Korsinsky?

With over 20 years of experience in securities litigation, Levi & Korsinsky has built a reputable history of recovering substantial amounts for shareholders who have suffered losses due to corporate misconduct. Their track record includes participation in high-stakes cases, and they have consistently ranked among the top securities litigation firms in the U.S., according to ISS Securities Class Action Services. Their dedicated team is committed to providing expert representation and ensuring that the rights of investors are upheld.

This alert serves as a critical reminder for all investors who hold shares in Caribou Biosciences, Inc. Take action now to understand your rights and options regarding this impending lawsuit against the company. Don’t hesitate to contact Levi & Korsinsky to ensure you are adequately represented in this crucial matter.

For more details, you can also visit Levi & Korsinsky's official website.